165 related articles for article (PubMed ID: 14501009)
1. Immunological approach for the treatment of Alzheimer's disease.
Solomon B
J Mol Neurosci; 2003; 20(3):283-6. PubMed ID: 14501009
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.
Solomon B
DNA Cell Biol; 2001 Nov; 20(11):697-703. PubMed ID: 11788047
[TBL] [Abstract][Full Text] [Related]
3. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease.
Zhang J; Wu X; Qin C; Qi J; Ma S; Zhang H; Kong Q; Chen D; Ba D; He W
Neurobiol Dis; 2003 Dec; 14(3):365-79. PubMed ID: 14678754
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta.
Wang J; Hara H; Makifuchi T; Tabira T
J Alzheimers Dis; 2008 Jun; 14(2):161-73. PubMed ID: 18560128
[TBL] [Abstract][Full Text] [Related]
5. Immunological approaches as therapy for Alzheimer's disease.
Solomon B
Expert Opin Biol Ther; 2002 Dec; 2(8):907-17. PubMed ID: 12517269
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination.
Solomon B
J Alzheimers Dis; 2006; 9(3 Suppl):433-8. PubMed ID: 16914882
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease and immunotherapy.
Solomon B
Curr Alzheimer Res; 2004 Aug; 1(3):149-63. PubMed ID: 15975063
[TBL] [Abstract][Full Text] [Related]
8. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.
Wang CM; Devries S; Camboni M; Glass M; Martin PT
Neurobiol Dis; 2010 Sep; 39(3):409-22. PubMed ID: 20493257
[TBL] [Abstract][Full Text] [Related]
9. Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.
Sambamurti K; Pappolla MA; Jagannatha Rao KS
J Alzheimers Dis; 2008 Jun; 14(2):175-7. PubMed ID: 18663823
[No Abstract] [Full Text] [Related]
10. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
[TBL] [Abstract][Full Text] [Related]
11. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
Levites Y; Jansen K; Smithson LA; Dakin R; Holloway VM; Das P; Golde TE
J Neurosci; 2006 Nov; 26(46):11923-8. PubMed ID: 17108166
[TBL] [Abstract][Full Text] [Related]
12. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
[TBL] [Abstract][Full Text] [Related]
13. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
Cattepoel S; Hanenberg M; Kulic L; Nitsch RM
PLoS One; 2011 Apr; 6(4):e18296. PubMed ID: 21483675
[TBL] [Abstract][Full Text] [Related]
14. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model.
Fukuchi K; Accavitti-Loper MA; Kim HD; Tahara K; Cao Y; Lewis TL; Caughey RC; Kim H; Lalonde R
Biochem Biophys Res Commun; 2006 May; 344(1):79-86. PubMed ID: 16630540
[TBL] [Abstract][Full Text] [Related]
16. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.
Frenkel D; Dewachter I; Van Leuven F; Solomon B
Vaccine; 2003 Mar; 21(11-12):1060-5. PubMed ID: 12559780
[TBL] [Abstract][Full Text] [Related]
17. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
18. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.
Fukuchi K; Tahara K; Kim HD; Maxwell JA; Lewis TL; Accavitti-Loper MA; Kim H; Ponnazhagan S; Lalonde R
Neurobiol Dis; 2006 Sep; 23(3):502-11. PubMed ID: 16766200
[TBL] [Abstract][Full Text] [Related]
19. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
20. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
Solomon B
Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
